Discontinued — last reported Q4 '25
MetLife Interest Paid decreased by 15.3% to $243.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 8.5%, from $224.00M to $243.00M. Over 4 years (FY 2021 to FY 2025), Interest Paid shows an upward trend with a 3.3% CAGR. This is a positive signal — lower values indicate better performance for this metric.
An increase in interest paid relative to debt levels may signal rising borrowing costs or higher leverage, while a decrease may indicate debt reduction or refinancing at lower rates.
The total cash outflow for interest payments on debt obligations, typically disclosed as a supplemental item in the cash...
Essential for comparing the cost of capital and debt burden across peers in the pharmaceutical industry.
interest_paid| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $287.00M | $166.00M | $308.00M | $150.00M | $285.00M | $156.00M | $314.00M | $183.00M | $289.00M | $206.00M | $311.00M | $231.00M | $296.00M | $223.00M | $287.00M | $224.00M | $283.00M | $247.00M | $287.00M | $243.00M |
| QoQ Change | — | -42.2% | +85.5% | -51.3% | +90.0% | -45.3% | +101.3% | -41.7% | +57.9% | -28.7% | +51.0% | -25.7% | +28.1% | -24.7% | +28.7% | -22.0% | +26.3% | -12.7% | +16.2% | -15.3% |
| YoY Change | — | — | — | — | -0.7% | -6.0% | +1.9% | +22.0% | +1.4% | +32.1% | -1.0% | +26.2% | +2.4% | +8.3% | -7.7% | -3.0% | -4.4% | +10.8% | +0.0% | +8.5% |